Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumors 1

Interventions

Cisplatin 7Pemetrexed 6atezolizumab 5Carboplatin 4tislelizumab 3Paclitaxel 3Leucovorin 3Filgrastim 3Etoposide 3vistusertib 2pembrolizumab 2Vincristine 2Topotecan 2Temozolomide 2Tegafur 2Sorafenib 2Irinotecan 2Immunoenzyme Techniques 2Gemcitabine 2Docetaxel 2Cyclophosphamide 2zirconium-89-trastuzumab 1vandetanib 1toripalimab 1temsirolimus 1tanespimycin 1talazoparib 1soblidotin 1selinexor 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × balugrastim × Other solid neoplasm × Clear all
NCT01940601 2015-01-14

Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Withdrawn
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡